Results 121 to 130 of about 304,324 (330)
The Relation of Immunoglobulin Class, Pattern of Antinuclear Antibody, and Complement-Fixing Antibodies to DNA in Sera from Patients with Systemic Lupus Erythematosus* [PDF]
Naomi F. Rothfield, B. David Stollar
openalex +1 more source
Objective Tumornecrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to nonresponse or adverse effects.
Chuan Fu Yap+12 more
wiley +1 more source
Antibodies to Native and Denatured Deoxyribonucleic Acid in Systemic Lupus Erythematosus* [PDF]
Roberto M. Arana, Maxime Seligmann
openalex +1 more source
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source
Slowly Sedimenting Mercaptoethanol-resistant Antinuclear Factors Related Antigenically to M Immunoglobulins (γ1M-Globulin) in Patients with Systemic Lupus Erythematosus * [PDF]
Naomi F. Rothfield+2 more
openalex +1 more source
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from Part A (SLE) or Part B (CLE with/without SLE) of the randomized phase II LILAC trial who received ...
Richard Furie+8 more
wiley +1 more source
Loss of TRIM21 drives UVB‐induced systemic inflammation by regulating DNA‐sensing pathways
Background Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light B (UVB) driving lupus flares and triggering symptoms like joint pain, fatigue, and cutaneous lesions. Although the mechanism(s) linking UVB exposure to systemic effects are unclear, type I interferons (IFNs) are known to play a ...
Gantsetseg Tumurkhuu+17 more
wiley +1 more source
Systemic Lupus Erythematosus Disease Activity Index
semanticscholar +1 more source